GPT and neutropenia: In the third-grade AE, the use of NP/G plus necuparanib presented thrombocytopenia (27% vs. 5%), anemia (22% vs. 1%), fatigue (13% vs. 11%), elevated ALT (alanine aminotransferase) (12% vs. 0%), elevated AST (enzyme aspartate aminotransferase) (10% vs. 2%), and diarrhea (12% vs. 0%), while in the fourth-grade AE, two events were observed in a higher percentage of affected patients in the group with placebo: neutropenia and febrile neutropenia.